字幕表 動画を再生する 英語字幕をプリント Chimeric antigen receptor therapy or CAR T-cell therapy is an emerging immunotherapy designed specifically to target a patient's cancer cells. To date, the most successful of these therapies CD19 CAR therapy targets B cells in Leukemia and Lymphoma. A patient begins treatment by undergoing apheresis to extract normal T-cells. In the laboratory, a modified virus either a lentivirus or retrovirus transfers targeted genetic information into the T-cells where it is incorporated into the genome. Newly synthesized CD19 CAR proteins are then expressed on the T-cells surface. The altered T-cells are expanded in vitro and delivered to the patient by infusion. In the body, the engineered receptors bind to specific antigens expressed by the target cancer cells, killing them. With hundreds of trials currently being conducted worldwide, engineered cell therapies like CAR T-cell therapy have the potential to transform treatment for cancer and other diseases.